We are Roche

A healthier future. It’s what drives us to innovate.

To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.

Creating a world where we all have more time with the people we love.

That’s what makes us Roche.

In the spotlight

How we improved outcomes for patients around the world

Roche publishes its Full Year results for 2024

For Investors

Discover great stories about
SciencePartnershipCulturePatientsSociety

Perspectives and powerful moments that shape healthcare.

Improving the patient journey

From diagnostics to therapeutics, Roche is innovating new options for people living with Alzheimer’s disease

AI and machine learning: revolutionising drug discovery and transforming patient care

The development of new medicines is complex. Leveraging artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize drug discovery by enhancing data analysis and prediction.

Pioneering in Antibiotics

Roche is a leader and innovator in addressing antimicrobial resistance (AMR). We are investing in new antibiotics and diagnostics and working with partners to bring hope through breakthroughs.

Advancing diabetes care: how predictive technology improves daily management

Diagnosed with type 1 diabetes in 1985, Hanna Boëthius faced significant struggles due to the limited tools available. Over the years, advancements in technology have transformed diabetes management.

1/1

Explore more stories

We will prevent diseases by identifying high-risk patients early to enable timely use of medicines.

Our Strategy

We will stop diseases by accurately diagnosing and stratifying patients to halt disease progression through targeted medicines.

Our Diagnostics Solutions

We will cure diseases by identifying the cause of disease in order to restore health through curative medicines.

Our Pharma Solutions

Careers

Join us!

Learn more about exciting career opportunities at Roche, one of the world's leading research-based healthcare companies.

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)

Roche Accessibility Statement

At Roche, we are committed to ensuring that our websites and digital resources are accessible to all users.

1/2